Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer

BACKGROUND: Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally effective VEGFR‐2 tyrosine kinase inhibitor (TKI). This pilot study aims to evaluate the tolerability, pharmacokinetic profile, and anti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Transl Med
Hauptverfasser: Zhang, Zhonghan, Zhang, Yang, Luo, Fan, Ma, Yuxiang, Fang, Wenfeng, Zhan, Jing, Li, Su, Yang, Yunpeng, Zhao, Yuanyuan, Hong, Shaodong, Zhou, Ting, Zhang, Yaxiong, Zhao, Shen, Huang, Yan, Zhao, Hongyun, Zhang, Li
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Research Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403827/
https://ncbi.nlm.nih.gov/pubmed/32508029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.33
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge